| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sundeep Khosla | Q42164143 |
| P2093 | author name string | Matthew T Drake | |
| Bart L Clarke | |||
| P2860 | cites work | Bisphosphonate therapy for children and adolescents with secondary osteoporosis | Q24243298 |
| The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins | Q24684244 | ||
| Rho GTPases and the actin cytoskeleton | Q27860579 | ||
| Vitamin D deficiency | Q27860616 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws | Q28240354 | ||
| Bisphosphonates: from bench to bedside | Q28251212 | ||
| Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment | Q28278528 | ||
| Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis | Q29619487 | ||
| Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. | Q31841626 | ||
| Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. | Q31921266 | ||
| Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study | Q33297907 | ||
| Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin | Q33902085 | ||
| Severely suppressed bone turnover: a potential complication of alendronate therapy | Q33983792 | ||
| Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. | Q33995702 | ||
| Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis | Q34003925 | ||
| Prolonged bisphosphonate release after treatment in children | Q79907020 | ||
| Clinical practice. Paget's disease of bone | Q80088271 | ||
| Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation | Q80119312 | ||
| Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement | Q80120158 | ||
| Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis | Q80129380 | ||
| The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)] | Q80156775 | ||
| Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial | Q80307867 | ||
| Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty | Q80442873 | ||
| Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates | Q80586247 | ||
| Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis | Q83296260 | ||
| Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid | Q83938052 | ||
| Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone | Q83976296 | ||
| Transmission of human herpesvirus 8 by blood transfusion | Q95814375 | ||
| Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. | Q53803388 | ||
| Alendronate and atrial fibrillation. | Q55043822 | ||
| Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids | Q57086737 | ||
| Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial | Q57224477 | ||
| Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey | Q57417197 | ||
| Alendronate for the Treatment of Osteoporosis in Men | Q57450326 | ||
| Intravenous pamidronate attenuates bone density loss after acute spinal cord injury | Q57711945 | ||
| A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma | Q57786339 | ||
| Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone | Q57904055 | ||
| Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 | ||
| Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research | Q58216587 | ||
| Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis | Q58971133 | ||
| Yearly zoledronic acid in postmenopausal osteoporosis | Q58971184 | ||
| Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate | Q58971203 | ||
| Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users | Q58974243 | ||
| Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group | Q59616816 | ||
| Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis | Q61716195 | ||
| The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised r | Q71646365 | ||
| Optimal calcium intake | Q71842084 | ||
| Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group | Q71890854 | ||
| Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency | Q72827947 | ||
| Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women | Q73150132 | ||
| Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials | Q73504275 | ||
| Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis | Q73794664 | ||
| Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate | Q73892733 | ||
| Combination therapy for postmenopausal osteoporosis | Q74177997 | ||
| Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation | Q74316545 | ||
| Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy | Q79137459 | ||
| Experience with bisphosphonates in osteogenesis imperfecta | Q79856017 | ||
| Pamidronate reduces bone loss after allogeneic stem cell transplantation | Q79885177 | ||
| Alendronate prevents further bone loss in renal transplant recipients. | Q43791666 | ||
| Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study | Q43791673 | ||
| Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density | Q43842242 | ||
| Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic | Q43968160 | ||
| The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis | Q44042152 | ||
| Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer | Q44083704 | ||
| Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | Q44198095 | ||
| Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis | Q44202451 | ||
| Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial | Q44234273 | ||
| Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer | Q44456773 | ||
| Alendronate treatment in children with osteogenesis imperfecta. | Q44563352 | ||
| Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma | Q44564597 | ||
| Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases | Q44572717 | ||
| The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis | Q44590934 | ||
| The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis | Q44590937 | ||
| Compliance with pharmacologic therapy for osteoporosis | Q44593075 | ||
| Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate | Q44599938 | ||
| Renal Failure with the Use of Zoledronic Acid | Q44628533 | ||
| Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study | Q44650876 | ||
| Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs | Q44695650 | ||
| Ten years' experience with alendronate for osteoporosis in postmenopausal women | Q44804093 | ||
| Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study | Q44835560 | ||
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 | ||
| Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial | Q44937090 | ||
| Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. | Q44961457 | ||
| Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases | Q45050162 | ||
| Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer | Q45056085 | ||
| Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation | Q45152628 | ||
| Alendronate and risedronate: reports of severe bone, joint, and muscle pain | Q45264997 | ||
| Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis | Q46288027 | ||
| Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome | Q46531818 | ||
| One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis | Q46644468 | ||
| Daily and cyclic parathyroid hormone in women receiving alendronate | Q46644473 | ||
| Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England | Q46679517 | ||
| Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. | Q46681443 | ||
| Efficacy of oral alendronate in children with osteogenesis imperfecta | Q46732093 | ||
| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors | Q46825147 | ||
| Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer | Q46884243 | ||
| Determinants of adherence to osteoporosis treatment in clinical practice | Q46991236 | ||
| Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study | Q47974874 | ||
| Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group | Q48527134 | ||
| Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study | Q51083403 | ||
| High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. | Q53558015 | ||
| Intravenous zoledronic acid in postmenopausal women with low bone mineral density | Q34116443 | ||
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 | ||
| Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism | Q34275146 | ||
| Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 | ||
| Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta | Q34476573 | ||
| Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial | Q34485941 | ||
| The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs | Q34523564 | ||
| Osteonecrosis of the jaw--do bisphosphonates pose a risk? | Q34572902 | ||
| Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study | Q34589366 | ||
| Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. | Q34617892 | ||
| Zoledronic acid and clinical fractures and mortality after hip fracture | Q34689802 | ||
| Teriparatide or alendronate in glucocorticoid-induced osteoporosis | Q34713779 | ||
| Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group | Q34747852 | ||
| Use of alendronate and risk of incident atrial fibrillation in women | Q34774594 | ||
| American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma | Q34803386 | ||
| The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta | Q34815287 | ||
| Modern approach to children with osteogenesis imperfecta | Q35065426 | ||
| Pamidronate-induced nephrotoxic tubular necrosis--a case report. | Q35667611 | ||
| Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis | Q36149052 | ||
| Cancer treatment-related bone loss: a review and synthesis of the literature | Q36410640 | ||
| Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature | Q36416668 | ||
| Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases | Q36561966 | ||
| Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma | Q36561970 | ||
| Markers of bone turnover for the management of patients with bone metastases from prostate cancer | Q36641310 | ||
| Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies | Q36694734 | ||
| Consensus and controversy regarding osteoporosis in the pediatric population | Q36943010 | ||
| Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial | Q38400853 | ||
| Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. | Q40482310 | ||
| Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial | Q40593773 | ||
| Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease | Q40756461 | ||
| Bisphosphonates: a review of their pharmacokinetic properties | Q41132404 | ||
| Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group | Q41697049 | ||
| Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. | Q42543174 | ||
| Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases | Q43563141 | ||
| Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study | Q43575868 | ||
| Effect of ibandronate on bone loss and renal function after kidney transplantation. | Q43652008 | ||
| Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer | Q43749401 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1032-1045 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Mayo Clin Proc | Q6538184 |
| P1476 | title | Bisphosphonates: mechanism of action and role in clinical practice | |
| P478 | volume | 83 |
| Q53245741 | 99mTc(CO)3-labeled pamidronate and alendronate for bone imaging. |
| Q40910592 | A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study |
| Q64937529 | A Unique Association of Osteogenesis Imperfecta with Bilateral Renal Osteodystrophy and Gastroenteritis in a Three-year-old Boy. |
| Q28972322 | A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency |
| Q37912798 | A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution |
| Q26859812 | A new approach to primary ovarian insufficiency |
| Q35854092 | A novel model of bisphosphonate-related osteonecrosis of the jaw in rats |
| Q36687909 | A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase |
| Q93177633 | A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers |
| Q37058392 | Accelerated bone mass senescence after hematopoietic stem cell transplantation |
| Q90450500 | Accessory Mental Foramen in a Patient with Mandibular Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) Lesion: A Case Report |
| Q38216355 | Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? |
| Q92910688 | Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) |
| Q33748998 | Administration of RANKL boosts thymic regeneration upon bone marrow transplantation |
| Q37098360 | Adverse bone health among children and adolescents growing up with HIV. |
| Q34614432 | Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. |
| Q34160511 | Aging, human immunodeficiency virus, and bone health |
| Q64925853 | Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple-blind clinical trial. |
| Q38699184 | Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line |
| Q92309852 | Alendronate-Functionalized Poly(2-oxazoline)s with Tunable Affinity for Calcium Cations |
| Q36289952 | An update on androgen deprivation therapy for prostate cancer |
| Q59126038 | Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair |
| Q38076462 | Animal models for bisphosphonate-related osteonecrosis of the jaws--an appraisal |
| Q38848170 | Anti-Resorptive Functions of Poly(ethylene sodium phosphate) on Human Osteoclasts. |
| Q37822779 | Antifracture efficacy of currently available therapies for postmenopausal osteoporosis |
| Q90398992 | Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer |
| Q38049751 | Antiresorptives and osteonecrosis of the jaw. |
| Q42964150 | Apoptosis and autoimmunity induced by clodronate in systemic lupus erythematosus mononuclear circulating cells. |
| Q60912922 | Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats |
| Q38701445 | Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase |
| Q33596535 | Association between alendronate and atypical femur fractures: a meta-analysis |
| Q33697117 | Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. |
| Q46228509 | Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy |
| Q36379448 | Atypical metatarsal fracture in a patient on long term bisphosphonate therapy |
| Q57163126 | Automated Scale Reduction of Nonlinear QSP Models With an Illustrative Application to a Bone Biology System |
| Q90913043 | Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation |
| Q64926713 | Berberine improves advanced glycation end products‑induced osteogenic differentiation responses in human periodontal ligament stem cells through the canonical Wnt/β‑catenin pathway. |
| Q51140195 | Better Osteoporotic Fracture Healing with Sintered Dicalcium Pyrophosphate (SDCP) Treatment: A Rat Femoral Fracture Model. |
| Q61453146 | Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review |
| Q91670934 | Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis |
| Q83015252 | Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V |
| Q34477058 | Bisphosphonate Remains Highly Localized After Elution From Porous Implants |
| Q36523054 | Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday |
| Q48283228 | Bisphosphonate guidelines for treatment and prevention of myeloma bone disease |
| Q33665130 | Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. |
| Q48148231 | Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies |
| Q39138688 | Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer |
| Q97425771 | Bisphosphonate-based nanocomposite hydrogels for biomedical applications |
| Q37996117 | Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants |
| Q93048274 | Bisphosphonate-induced Atypical Femoral Shaft Fracture |
| Q55364153 | Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. |
| Q31108809 | Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database |
| Q38493204 | Bisphosphonate-related osteonecrosis of the jaw: specificities |
| Q37957169 | Bisphosphonates and osteonecrosis of the jaw. |
| Q38311722 | Bisphosphonates and their influence on fracture healing: a systematic review |
| Q37946695 | Bisphosphonates as antimyeloma drugs |
| Q36471673 | Bisphosphonates as potential adjuvants for patients with cancers of the digestive system |
| Q37924117 | Bisphosphonates as radionuclide carriers for imaging or systemic therapy. |
| Q24202794 | Bisphosphonates for osteoarthritis |
| Q37055377 | Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. |
| Q24197839 | Bisphosphonates in multiple myeloma: a network meta-analysis |
| Q47290135 | Bisphosphonates in multiple myeloma: an updated network meta-analysis. |
| Q34905878 | Bisphosphonates pathway |
| Q37441608 | Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells |
| Q41810819 | Bisphosphonates: An update |
| Q38176927 | Bisphosphonates: therapeutics potential and recent advances in drug delivery |
| Q30831553 | Blood flow controls bone vascular function and osteogenesis. |
| Q93079405 | Bone Diseases in Patients with Chronic Liver Disease |
| Q47864550 | Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. |
| Q46274255 | Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome |
| Q34120101 | Bone cancer pain. |
| Q35626783 | Bone changes in alcoholic liver disease |
| Q34045789 | Bone disease in multiple myeloma: pathophysiology and management. |
| Q57823069 | Bone health and evaluation of bone mineral density in patients with premature ovarian insufficiency |
| Q64044632 | Bone metabolism in Langerhans cell histiocytosis |
| Q37873719 | Bone metastasis in prostate cancer: emerging therapeutic strategies. |
| Q39356298 | Bone-seeking agents for the treatment of bone disorders |
| Q47557023 | CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. |
| Q28481154 | Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis |
| Q90642673 | Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers |
| Q24597422 | Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review |
| Q37832414 | Can bisphosphonates play a role in the treatment of children with chronic kidney disease? |
| Q33567830 | Can denosumab be a substitute, competitor, or complement to bisphosphonates? |
| Q43205303 | Cancer pain physiology |
| Q45932492 | Cardiac Fibroblasts Adopt Osteogenic Fates and Can Be Targeted to Attenuate Pathological Heart Calcification. |
| Q33898842 | Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy |
| Q58593477 | Cathepsin K inhibition preserves compressive load in lumbar vertebrae of osteoporotic monkeys |
| Q35157851 | Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice |
| Q39412927 | Cellular and molecular mechanisms of alcohol-induced osteopenia |
| Q37775020 | Challenges in clinical patient management |
| Q35828143 | Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates |
| Q38105302 | Charcot neuroarthropathy of the foot and ankle |
| Q52890565 | Chenopodium ambrosioides L. extract prevents bone loss. |
| Q93160130 | Circaea mollis Siebold & Zucc. Alleviates postmenopausal osteoporosis in a mouse model via the BMP-2/4/Runx2 pathway |
| Q92888941 | Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density |
| Q53622474 | Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study). |
| Q92431274 | Clinical pathologies of bone fracture modelled in zebrafish |
| Q24653014 | Clinical practice. Primary ovarian insufficiency |
| Q40852576 | Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis. |
| Q90391771 | Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials |
| Q42583327 | Complications of pamidronate therapy in paediatric osteoporosis |
| Q47336507 | Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. |
| Q38748577 | Current Controversies in the Management of Myeloma Bone Disease |
| Q36890431 | Current and emerging therapies for the treatment of osteoporosis |
| Q41369617 | Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials |
| Q37970800 | Denosumab for the management of bone disease in patients with solid tumors |
| Q27022492 | Dental complications and management of patients on bisphosphonate therapy: A review article |
| Q37731222 | Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates |
| Q99631291 | Development and Clinical Application of Phosphorus-Containing Drugs |
| Q43038610 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis |
| Q92066467 | Development of bone seeker-functionalised microspheres as a targeted local antibiotic delivery system for bone infections |
| Q33850938 | Direct antitumour activity of zoledronic acid: preclinical and clinical data |
| Q37613765 | Drugs in development for toxoplasmosis: advances, challenges, and current status |
| Q45765840 | Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase. |
| Q34129152 | Effect of Bisphosphonates on the Progression of Degenerative Aortic Stenosis |
| Q37397269 | Effect of alendronate on bone remodeling around implant in the rat. |
| Q38472238 | Effect of alendronate on healing of extraction sockets and healing around implants. |
| Q86053795 | Effect of alendronate on the mandible and long bones: an experimental study in vivo |
| Q64068776 | Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study |
| Q51832370 | Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. |
| Q92056333 | Effects of Adding Intravenous Pamidronate to Ongoing Menopausal Hormone Therapy in Postmenopausal Korean Women with Low Bone Mineral Density |
| Q53142951 | Effects of alendronate on lumbar posterolateral fusion using hydroxyapatite in rabbits. |
| Q38438261 | Effects of alendronate on the peri-implant bone in rats. |
| Q38268978 | Effects of maternal bisphosphonate use on fetal and neonatal outcomes |
| Q64115997 | Effects of ultraviolet treatment and alendronate immersion on osteoblast-like cells and human gingival fibroblasts cultured on titanium surfaces |
| Q55116815 | Effects of zoledronic acid on physiologic bone remodeling of condylar part of TMJ: a radiologic and histomorphometric examination in rabbits. |
| Q98614822 | Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial |
| Q37708212 | Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial |
| Q38298725 | Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. |
| Q35973243 | Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. |
| Q91614767 | Efficacy of pamidronate in children with chronic non-bacterial osteitis using whole body MRI as a marker of disease activity |
| Q90226321 | Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption |
| Q42332209 | Emerging potential for bisphosphonates in the treatment of axial spondyloarthritis |
| Q34161867 | Emerging therapeutic opportunities for skeletal restoration |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q33716919 | Estrogen depletion and drug treatment alter the microstructure of type I collagen in bone |
| Q39030985 | Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients |
| Q38631395 | Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review |
| Q41415611 | Fabrication and physicochemical characterization of porous composite microgranules with selenium oxyanions and risedronate sodium for potential applications in bone tumors. |
| Q35112085 | Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics. |
| Q52331539 | Graphene-Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization. |
| Q56961932 | Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer |
| Q89885670 | Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study |
| Q41481543 | Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury |
| Q90273735 | Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis |
| Q41426868 | IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. |
| Q46295408 | Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function |
| Q42353384 | Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial |
| Q84033281 | Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B |
| Q55437454 | Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. |
| Q47265797 | Identifying a combined biomarker for bisphosphonate-related osteonecrosis of the jaw. |
| Q64084531 | Immune Modulation by Transplanted Calcium Phosphate Biomaterials and Human Mesenchymal Stromal Cells in Bone Regeneration |
| Q90599028 | Immunohistochemical Femoral Nerve Study Following Bisphosphonates Administration |
| Q64120300 | Immunoregulation of macrophages by dynamic ligand presentation via ligand-cation coordination |
| Q36594973 | Impact and risk factors of post-stroke bone fracture |
| Q37354985 | In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice. |
| Q50691033 | In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method. |
| Q57295723 | Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing |
| Q34599958 | Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation |
| Q39199332 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. |
| Q48262033 | Interactions between Clinically Used Bisphosphonates and Bone Mineral: from Coordination Chemistry to Biomedical Applications and Beyond. |
| Q38766431 | Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. |
| Q24198280 | Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy |
| Q37603941 | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. |
| Q84074575 | Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer? |
| Q48023175 | La(iii) biodistribution profiles from intravenous and oral dosing of two lanthanum complexes, La(dpp)3 and La(XT), and evaluation as treatments for bone resorption disorders |
| Q38617388 | Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta |
| Q61797341 | Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer |
| Q36027214 | Management of atypical femoral fracture: a scoping review and comprehensive algorithm |
| Q37337113 | Management of osteoporosis in the aging male: focus on zoledronic acid |
| Q41196623 | Managing bisphosphonate-related osteonecrosis of the jaws with xenografts: a case report |
| Q34106431 | Managing osteoporosis in postmenopausal women |
| Q35400080 | Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. |
| Q51183940 | Material properties of bone in the femoral head treated with ibandronate and BMP-2 following ischemic osteonecrosis. |
| Q46451867 | Mathematical Model of Bone Remodeling Captures the Antiresorptive and Anabolic Actions of Various Therapies |
| Q64953317 | Mechanism of CK2.3, a Novel Mimetic Peptide of Bone Morphogenetic Protein Receptor Type IA, Mediated Osteogenesis. |
| Q64985581 | Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3. |
| Q64276494 | Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat |
| Q39700905 | Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model. |
| Q91212184 | Medication-related osteonecrosis: Patients with a hidden risk of MRONJ |
| Q58885355 | Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis |
| Q56985914 | Microwave-driven synthesis of bisphosphonate nanoparticles allows in vivo visualisation of atherosclerotic plaque |
| Q53743085 | Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors. |
| Q94397831 | Molecular pathogenesis and therapeutic strategies of human osteosarcoma |
| Q38763133 | Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth |
| Q41855288 | Multiple fractures, pain, and severe disability in a patient with adult-onset hypophosphatasia |
| Q34038854 | Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics |
| Q50053775 | Nano-confinement-driven enhanced magnetic relaxivity of SPIONs for targeted tumor bioimaging. |
| Q39198933 | Nephrotoxicity of anticancer treatment |
| Q47710981 | Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. |
| Q60922830 | Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts |
| Q48101911 | Non-complex reconstructive techniques in the management of BRONJ: a case series of patient-related outcomes |
| Q89187407 | Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care |
| Q36240108 | Novel applications of statins for bone regeneration |
| Q35899482 | Nur77 prevents excessive osteoclastogenesis by inducing ubiquitin ligase Cbl-b to mediate NFATc1 self-limitation. |
| Q55237271 | Observational study of the bisphosphonate-related osteonecrosis of jaws. |
| Q35229899 | Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort |
| Q52655586 | Osteogenesis imperfecta and therapeutics. |
| Q43479103 | Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects |
| Q34178759 | Osteoporosis and gastrointestinal disease |
| Q88900139 | Osteoporosis following heart transplantation and immunosuppressive therapy |
| Q35173349 | Osteoporosis in chronic obstructive pulmonary disease |
| Q40290624 | Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q90729095 | Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development |
| Q37791155 | Pharmacogenetics of Osteoporosis-Related Bone Fractures: Moving Towards the Harmonization and Validation of Polymorphism Diagnostic Tools |
| Q90487338 | Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway |
| Q89483219 | Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration |
| Q35480967 | Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients |
| Q52687655 | Prevention of ovariectomy-induced osteoporosis in rats : Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate. |
| Q26852821 | Prevention of steroid-induced low bone mineral density in children with renal diseases: a systematic review |
| Q36687880 | Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate |
| Q46276532 | Primary cilium is required for the stimulating effect of icaritin on osteogenic differentiation and mineralization of osteoblasts in vitro. |
| Q39267549 | Progress in tumor-associated macrophage (TAM)-targeted therapeutics |
| Q39143187 | Proline modulates the effect of bisphosphonate on calcium levels and adenosine triphosphate production in cell lines derived from bovine Echinococcus granulosus protoscoleces. |
| Q90866188 | Protein and bone health across the lifespan |
| Q103034302 | Quantification of the bisphosphonate alendronate using capillary electrophoresis mass spectrometry with dynamic pH barrage junction focusing |
| Q35228787 | RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects |
| Q89838580 | Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany |
| Q36259554 | Removal of pamidronate from bone in rats using systemic and local chelation |
| Q64294389 | Response to Zoledronic Acid in Patients with Active Paget's Disease of Bone: A Retrospective Study |
| Q38187901 | Review: epidemiology and pathophysiology of atypical femur fractures |
| Q36820214 | Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study |
| Q40100089 | Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis |
| Q35068631 | Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis |
| Q44747076 | Risks and benefits of long-term bisphosphonate therapy |
| Q64911041 | Role of bisphosphonates in the management of acute Charcot foot. |
| Q48294628 | Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. |
| Q37475161 | SEOM Clinical Guideline for bone metastases from solid tumours (2016). |
| Q51342272 | Self-assembling bisphosphonates into nanofibers to enhance their inhibitory capacity on bone resorption. |
| Q50061495 | Self-healing hydrogels formed by complexation between calcium ions and bisphosphonate-functionalized star-shaped polymers. |
| Q45963261 | Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis? |
| Q90182098 | Severe bilateral Legg-Calvé-Perthes resolved with pamidronate in combination with casts, physiotherapy and adductor tenotomy: a pictorial essay over 11 years |
| Q38218704 | Sex disparities in neuro-ophthalmologic disorders |
| Q42910875 | Short‐term zoledronic acid reduces trabecular bone remodeling in dogs |
| Q34753158 | Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? |
| Q37615260 | Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity |
| Q89280856 | Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease |
| Q37354085 | Skeletal metastasis: treatments, mouse models, and the Wnt signaling |
| Q64254391 | Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing |
| Q41008310 | Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model. |
| Q40973749 | Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw. |
| Q39569410 | Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates |
| Q41036893 | Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report |
| Q36152236 | Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report |
| Q35867314 | Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. |
| Q45587240 | Synthesis and biological evaluation of bisphosphonate compound labeled with (99m)Tc(CO)3(+). |
| Q28829845 | Synthesis of composite magnetic nanoparticles Fe3O4 with alendronate for osteoporosis treatment |
| Q46396656 | Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. |
| Q92589455 | Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw |
| Q37524684 | Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. |
| Q58117324 | Targeted Nanomedicine to Treat Bone Metastasis |
| Q27030812 | Targeted microbubbles: a novel application for the treatment of kidney stones |
| Q38698660 | Targeting collagen for diagnostic imaging and therapeutic delivery |
| Q82413764 | Targeting osteoclast-osteoblast communication |
| Q38626370 | The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution. |
| Q52690066 | The Effect of Inhalant Organic Dust on Bone Health. |
| Q61796517 | The Effect of Polydeoxyribonucleotide Extracted from Salmon Sperm on the Restoration of Bisphosphonate-Related Osteonecrosis of the Jaw |
| Q89884796 | The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report |
| Q47134813 | The Potential of microRNAs for Stem Cell-based Therapy for Degenerative Skeletal Diseases. |
| Q36743799 | The Role of KV7.3 in Regulating Osteoblast Maturation and Mineralization |
| Q64080243 | The Role of Tocotrienol in Preventing Male Osteoporosis-A Review of Current Evidence |
| Q31156585 | The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data. |
| Q47729932 | The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats |
| Q48794992 | The most frequent electrolyte disorders in the emergency department : what must be done immediately? |
| Q38717986 | The role of radiotherapy in bone metastases: A critical review of current literature |
| Q90470510 | The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate |
| Q90290365 | Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue |
| Q36147288 | Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. |
| Q53565333 | Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. |
| Q90015665 | Tissue engineered models of healthy and malignant human bone marrow |
| Q48875320 | Tissue-Engineered Model of Human Osteolytic Bone Tumor |
| Q89142853 | Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast-Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis |
| Q35191865 | Tooth alterations in areas of bisphosphonate-induced osteonecrosis |
| Q33577356 | Total hip arthroplasty in patients with Paget's disease of bone: A systematic review |
| Q57110556 | Translational models of prostate cancer bone metastasis |
| Q91672626 | Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis |
| Q37987820 | Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature |
| Q38050104 | Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to February 2012. |
| Q57346992 | Unprecedented Control of Selectivity in Nickel-Catalyzed Hydrophosphorylation of Alkynes: Efficient Route to Mono- and Bisphosphonates |
| Q37812617 | Use of medications and risk of revision after primary total hip arthroplasty |
| Q33958113 | Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. |
| Q36729340 | Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment |
| Q83588890 | Wnt signaling as a therapeutic target for bone diseases |
| Q98463617 | Zoledronate and SPIO dual-targeting nanoparticles loaded with ICG for photothermal therapy of breast cancer tibial metastasis |
| Q40613636 | Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip. |
| Q34025648 | Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers |
| Q42786117 | Zoledronic acid in myeloma: MRC Myeloma IX. |
| Q47139370 | Zoledronic acid in pediatric metabolic bone disorders |
| Q37688626 | Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma |
Search more.